Pharma BD Deal Intelligence
Two-asset China-origin in-license broadening Nuvectis into complement and BRAF oncology
Full analysis, sources & comparables →Nuvectis Pharma in-licensed exclusive worldwide ex-China rights to two clinical-stage compounds from Haisco Pharmaceutical Group: NXP100, a once-daily oral Complement Factor B inhibitor with two MAAs under review in China for paroxysmal nocturnal hemoglobinuria (PNH), and NXP200, an oral paradox-breaker BRAF inhibitor in Phase 1b in China for BRAF-mutated solid tumors. Haisco receives up to $40M in upfront/near-term payments, up to $1.421B in milestones, plus tiered royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Nuvectis Pharma, Inc. / Haisco Pharmaceutical Group Co., Ltd. (this deal) | 2026 | $1.5B | 59 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2026 deals · Hematology deals